Pricing Log in Create free account
Saturday 17 October 2026 Export ICCC’s income statement to Excel — free account

ImmuCell Corporation

ICCC Healthcare Biotechnology

ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024. In the quarter to June 2026, revenue grew 11.5%, EPS grew 233.3%, free cash flow grew 54.9% and total debt fell 15.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

10.75 0.19 +1.80%
Market cap
$95.9M
P/E
126×
Fwd P/E
−779×
Dividend yield
—
F-score
7/9
Altman Z
2.80
Beneish M
−3.10
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.17
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 2 — — — — — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership 37.45%

Capital & Financial Ratios $m

Market Cap 95.90
Revenue 30.68
Net Income 0.79
Free Cash Flow 4.23
Net Debt (0.56)
Current Ratio 4.75 (at or above 1.5: strong)
Debt/Equity 0.26 (at or below 0.5: strong)
P/E ratio 126.00 (above 35: high)
Fwd P/E (779.00) (negative: loss-making)
P/S ratio 3.15
P/B ratio 3.08
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth 25.15% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.1×, against a ten-year median of 2.9×; over the ten years it ranged from 1.5× in 2016 to 5.6× in 2021.
P/E against its own 10 years 75.50%
10-year low 10-year high
P/S against its own 10 years 66.83%
10-year low 10-year high
P/B against its own 10 years 98.67%
10-year low 10-year high
EV/Sales against its own 10 years 64.43%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 4 4 9
Receivables 2 4 3 3
Inventory 8 7 9 9
Other — — — —
11 15 17 21
2023 2024 2025 Q'26
Payables 2 2 2 3
ST’ Debt 1 1 2 2
Other — — — —
4 4 4 4

Compound Annual Growth %

10y 5y 3y
Sales 10.45% 12.50% 14.19%
Cash Flow (1.57%) 13.48% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 9.81% (0.87%) (3.79%)

Revenue $m

Mar Jun Sep Dec Year
’26 10 7 — — —
’25 8 6 6 8 28
’24 7 5 6 8 26
’23 3 4 5 5 17
’22 6 4 5 4 19
’21 4 5 5 5 19
’20 5 3 4 4 15
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 4 3 — — —
’25 2 2 (1) 0 2
’24 0 1 (1) 0 0
’23 (3) (1) (1) (1) (5)
’22 1 0 (1) (1) (2)
’21 (1) 1 0 1 1
’20 1 1 (1) 0 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 2 — — —
’25 1 1 (2) 0 1
’24 0 0 (1) 0 0
’23 (3) (1) (1) (1) (7)
’22 0 (1) (2) (3) (6)
’21 (1) 0 0 0 (2)
’20 0 0 (2) 0 (3)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.21 0.20 — — —
’25 0.16 0.06 (0.02) (0.31) (0.12)
’24 (0.06) (0.20) (0.09) 0.06 (0.26)
’23 (0.30) (0.18) (0.12) (0.15) (0.75)
’22 0.07 (0.09) (0.08) (0.22) (0.32)
’21 (0.06) 0.02 0.02 0.01 (0.01)
’20 (0.02) (0.11) (0.04) 0.03 (0.14)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.76 5.00 6.38 4.70 3.70 5.73 5.98 4.26 3.34 4.28

Analyst estimates 2026–2028

Powerpack
High 8.29 9.25 9.30 8.28 8.13 13.20 10.96 7.84 5.82 7.60
People
People Employees 45 47 51 54 61 67 74 79 75 73
Revenue/emp, $m 0.21 0.22 0.22 0.25 0.25 0.29 0.25 0.22 0.35 0.38
Income, $m
Income, $m Revenue 10 10 11 14 15 19 19 17 26 28
Gross margin, % 56.80 50.06 47.28 49.11 44.73 44.98 41.19 22.15 29.97 41.40
EBT 1 0 (2) (1) (1) 0 (2) (6) (2) (1)
EBT margin, % 7.95 (4.20) (16.93) (9.24) (6.73) (0.36) (13.39) (33.02) (8.10) (3.72)
Net income 1 0 (2) (1) (1) 0 (2) (6) (2) (1)
Depreciation 1 1 2 2 2 2 2 3 3 3
Per share, $
Per share, $ Revenue 2.26 2.11 2.00 2.01 2.13 2.53 2.40 2.26 3.24 3.06
Earnings 0.12 (0.03) (0.42) (0.19) (0.14) (0.01) (0.32) (0.75) (0.26) (0.12)
Cash flow (0.05) 0.24 (0.07) 0.03 0.18 0.13 (0.20) (0.60) 0.04 0.27
Capex (0.84) (3.58) (0.32) (0.14) (0.56) (0.34) (0.51) (0.24) (0.06) (0.13)
Free cash flow (0.89) (3.34) (0.39) (0.10) (0.38) (0.22) (0.71) (0.85) (0.01) 0.14
Book value 4.67 4.77 3.96 4.25 3.92 4.29 3.92 3.23 3.37 3.00
Shares, m 4 5 5 7 7 8 8 8 8 9
Valuation, ×
Valuation, × P/E 43.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2.63 3.92 3.52 2.56 2.80 3.16 2.70 2.22 1.59 2.01
P/B 1.28 1.73 1.78 1.21 1.52 1.86 1.65 1.55 1.53 2.05
EV/Sales 1.84 4.42 4.18 2.53 2.90 3.10 2.94 2.85 1.84 2.20
EV/FCF (4.64) (2.79) (21.33) (49.11) (16.40) (36.41) (9.92) (7.58) (472.81) 48.22
Cash, $m
Cash, $m Operating cash flow 0 1 0 0 1 1 (2) (5) 0 2
Capex (4) (18) (2) (1) (4) (3) (4) (2) 0 (1)
Free cash flow (4) (17) (2) (1) (3) (2) (6) (7) 0 1
Balance, $m
Balance, $m Working capital 12 5 4 11 10 14 11 7 11 13
Total debt 3 9 10 8 9 9 10 12 11 9
Net debt (8) 5 7 0 2 (1) 4 11 7 5
Shareholders’ equity 20 24 22 29 28 33 30 25 28 27
Returns, %
Returns, % ROA 2.59 (0.57) (6.93) (3.63) (2.59) (0.18) (5.58) (13.03) (4.85) (2.37)
ROIC 4.59 (0.53) (3.12) (2.08) (2.89) 0.51 (4.13) (9.98) (2.99) 3.19
ROE 3.35 (0.78) (10.24) (5.11) (3.57) (0.26) (7.92) (20.86) (8.21) (3.81)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

ImmuCell Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MIST Milestone Pharmaceuticals Inc. $98.9M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
CBUS Cibus, Inc. $98.6M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%) Compare
PMVP PMV Pharmaceuticals, Inc. $97.4M — (loss-making) — — n/m +20.27% (above 0%: growing) 0.00% 0.00% Compare
NRXS Neuraxis, Inc. $97.2M — (loss-making) — (loss-making) +115.71% (above 0%: growing) n/m +29.76% (above 0%: growing) 85.87% (110.16%) Compare
IMUX Immunic, Inc. $96.9M — (loss-making) — — n/m −26.79% (below 0%: shrinking) 0.00% 0.00% Compare
ATRA Atara Biotherapeutics, Inc. $96.9M — (loss-making) — (loss-making) −96.42% (below 0%: shrinking) n/m +52.10% (above 0%: growing) 69.68% (749.21%) Compare
ANIX ANIXA BIOSCIENCES INC $96.7M — (loss-making) — (loss-making) 0.00% n/m −17.14% (below 0%: shrinking) 0.00% 0.00% Compare
ICCC ImmuCell Corporation $95.9M 126× — (loss-making) +11.50% (above 0%: growing) +233.33% (above 0%: growing) +54.86% (above 0%: growing) 33.92% 26.93%
RANI Rani Therapeutics Holdings, Inc. $94.8M — (loss-making) — (loss-making) 0.00% n/m −55.29% (below 0%: shrinking) 100.00% (516.86%) Compare
Median of peers $97.0M — — 0.00% — +1.56% 77.77% (313.51%)

All 614 Biotechnology stocks →

ImmuCell Corporation (ICCC) key facts

  • Strength: ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024.
  • ImmuCell Corporation (ICCC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ICCC traded at $10.75, a market capitalization of $95.9 million.
  • Return on equity was −3.81% and debt-to-equity 0.26.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 2.80 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

ImmuCell Corporation (ICCC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ICCC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com